<DOC>
	<DOC>NCT02555059</DOC>
	<brief_summary>The objective in this study is collecting post-marketing information on the safety and efficacy of Ciproxan injection under the routine clinical practice.</brief_summary>
	<brief_title>Special Drug Use Investigation of Ciproxan Injection in Pediatrics</brief_title>
	<detailed_description>This company-sponsored study is an one-arm, prospective, and, cohort-observational study in pediatrics (less than 15 years old) administered Ciproxan injection. All patients in the contracted institute should be enrolled into this study. Consequently 45 cases will be is planned to be enrolled in three-year period Target population is pediatrics with a diagnosis of complicated cystitis, pyelonephritis, cystic fibrosis, or anthrax infected by ciprofloxacin-active microorganisms, i.e. Bacillus anthracis, Escherichia coli, Pseudomonas aeruginosa. The treatment should be performed based on the product label in Japan. The standard observation will be performed until the last date of the treatment.</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Female and male pediatric patients (less than 15 years old) with a diagnosis of complicated cystitis, pyelonephritis, cystic fibrosis, or anthrax infected by ciprofloxacinactive microorganisms, i.e. Bacillus anthracis, Escherichia coli, Pseudomonas aeruginosa. Patients for whom the decision to initiate treatment with Ciproxan injection was made as per investigator's routine treatment practice.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>Japan</keyword>
	<keyword>Post-marketing surveillance</keyword>
</DOC>